Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Drugs in research
Every medicine and vaccine that a paper on Y is about, taken from each paper's abstract. Open one to see all its papers, newest first. Independent and not sponsored: no company has any say over what appears here.
Latest phase 2 and 3 results
Phase 2 · Haematology · Blood · 2026-11-12
In an ongoing phase 2a open-label study of 49 patients with phlebotomy-dependent polycythaemia vera, 4-weekly sapablursen lowered the weekly phlebotomy rate by 0.10 in both the 120/80 mg and 40 mg cohorts (P≤.0001). Anaemia and fatigue were the commonest adverse events.
Phase 3 · Neurology · JAMA · 2026-11-10
In 997 adults with acute ischaemic stroke (NIHSS 7–20) treated within 48 hours in China, 10 days of IV loberamisal vs placebo raised the proportion with mRS 0–1 at 90 days (69.7% vs 56.3%; RR 1.24, 95% CI 1.12–1.36), with similar adverse event rates.
Phase 3 · Haematology · Lancet Haematol · 2026-11-01
In 130 adults with KMT2A-rearranged leukaemia undergoing allogeneic HSCT in China, adding decitabine to busulfan-cyclophosphamide conditioning lowered 2-year relapse (12% vs 29%; HR 0·41, p=0·017), with similar grade 3–5 adverse events.
Funder named in the abstract: The National Natural Science Foundation of China, the National Key Research and Development Program of China, the Scienc
Phase 2 · Oncology · Lancet Oncol · 2026-11-01
In 160 transplant-ineligible adults with relapsed/refractory large B-cell lymphoma, CD20-CD19 CAR T-cell therapy zamto-cel lengthened event-free survival vs R-GemOx (median 6·21 vs 2·53 months; HR 0·39). Treatment-related deaths: 3% vs 1%.
Funder named in the abstract: Miltenyi Biomedicine
Phase 2 · Paediatrics · Pediatrics · 2026-11-01
In a phase IIb open-label trial of 240 healthy adolescents primed with BNT162b2, a PHH-1V protein booster produced higher Omicron BA.1 neutralising titres (measured in 90) than in young adults from an earlier trial, meeting non-inferiority; no related serious adverse events.
Phase 3 · Neurology · JAMA Neurol · 2026-11-01
10-year follow-up of two phase 3 trials in relapsing MS (n=1656): continuous ocrelizumab vs starting it after 2 years of interferon beta-1a lowered 48-week confirmed disability progression (HR 0.76; 95% CI 0.61-0.95). Adverse events did not rise in the extension.
Phase 3 · Oncology · Lancet · 2026-10-26
In 299 patients with mismatch repair-deficient advanced or recurrent endometrial cancer, first-line pembrolizumab beat carboplatin-paclitaxel on progression-free survival (median 38·2 vs 8·4 months; HR 0·57); overall survival not significant at interim analysis.
Funder named in the abstract: Merck Sharp & Dohme
Phase 3 · Oncology · Lancet · 2026-10-26
In 498 patients in China with EGFR-mutated advanced NSCLC progressing after EGFR-TKI therapy, the HER3-directed antibody-drug conjugate ruzaltatug rezetecan improved PFS vs platinum–pemetrexed (median 8·3 vs 5·4 months; HR 0·47) at interim analysis.
Funder named in the abstract: Jiangsu Hengrui Pharmaceuticals
Phase 3 · Oncology · Lancet Oncol · 2026-10-25
Phase 3 trial, 231 patients with locally advanced rectal cancer: short-course radiotherapy, camrelizumab and CAPOX vs long-course chemoradiotherapy then CAPOX. Primary pCR 39.8% vs 15.3%; interim 3-year event-free survival 91.3% vs 77.4% (HR 0.33).
Funder named in the abstract: Key Clinical Research Initiative Program of Union Hospital, National Key Technology Research and Development Programme o
Phase 3 · Oncology · Lancet · 2026-10-24
In 970 patients with refractory metastatic colorectal cancer in Japan, a 14-day trifluridine-tipiracil plus bevacizumab schedule was non-inferior to the 28-day schedule for overall survival (median 11·3 vs 10·3 months; HR 0·93), with less grade ≥3 neutropenia (13% vs 39%).
Funder named in the abstract: Japan Society for the Promotion of Science
Phase 3 · Haematology · Lancet · 2026-10-24
In 207 patients over 16 with sickle cell disease and recurrent pain crises, mitapivat vs placebo achieved haemoglobin response in 41% vs 3%, but the co-primary annualised pain crisis rate was not significantly reduced (2.6 vs 3.1; p=0.12). Serious adverse events: 20% vs 29%.
Funder named in the abstract: Agios Pharmaceuticals
Phase 3 · Nephrology · N Engl J Med · 2026-10-23
In an interim analysis of a phase 3 trial in adults with IgA nephropathy and persistent proteinuria, ravulizumab every 8 weeks lowered urinary protein-to-creatinine ratio at week 34 by 43.4% versus placebo (−46.6% vs −5.6%; P<0.001).
Funder named in the abstract: Alexion, AstraZeneca Rare Disease Unit
Phase 3 · Nephrology · N Engl J Med · 2026-10-23
Prespecified interim analysis of a phase 3 RCT in biopsy-proven IgA nephropathy: povetacicept 80 mg every 4 weeks reduced 24-h urine protein-to-creatinine ratio by 52.0% vs 4.3% with placebo at week 36 (first 199 of 557). Adverse events were similar (75% vs 78%).
Funder named in the abstract: Vertex Pharmaceuticals
Phase 3 · Dermatology · Br J Dermatol · 2026-10-19
In adults with moderate-to-severe pemphigus on prednisone, adding weekly subcutaneous efgartigimod did not improve complete remission on minimal prednisone by week 30 in pemphigus vulgaris vs placebo (35.5% vs 30.3%; OR 1.19, P=0.60). AEs 89.1% vs 76.0%.
Phase 3 · Infectious diseases · N Engl J Med · 2026-10-15
In 537 virally suppressed African adults with HIV and adherence challenges, injectable cabotegravir–rilpivirine every 8 weeks was noninferior to oral dolutegravir for viral load <50 at 48 weeks (91.0% vs 89.2%); confirmed virologic failure 1.9% vs 0%.
Funder named in the abstract: Johnson & Johnson
All drugs, A to Z (150)
#ABCDEFGHILMNOPRSTUVWZ